LineaRx, Inc.

LineaRx delivers enzymatically produced LinearDNA™ as an alternative to current plasmid-based DNA manufacturing processes with advantages of speed, purity, and scalability to support the next generation of nucleic acid-based therapies. Manufactured by a proprietary, large-scale polymerase chain reaction (‘PCR’)-based manufacturing platform, LinearDNA allows for the rapid and efficient cell-free production of high-fidelity DNA sequences. LinearDNA is relevant to a broad array of advanced therapeutics, including mRNA production, DNA vaccines, cell and gene therapies, as well as numerous veterinary medicine applications. Formed in 2018 to commercialize our parent company’s 20+ years of experience and leadership in enzymatic DNA production, LinearRx stands ready to deliver a new generation of DNA for the next generation of medicines.